Introduction
Cancer is amongst the most dominant non-communicable diseases and claims more lives than the combination of human immunodeficiency virus and acquired immunodeficiency syndrome (HIV and AIDS), malaria and tuberculosis worldwide. 1, 2 According to the World Health Organization, 3 8.2 million deaths and 14 million new cases of cancer were recorded globally in 2012. In South Africa, approximately 100 000 people are diagnosed with cancer annually, and numbers are expected to rise by 46% by 2030. 4 With approximately 12% of the South African population being infected by HIV and AIDS and resultantly being exposed to antiretroviral treatment, the risk of developing HIV-related cancers, such as Kaposi's sarcoma, is likely to create a great burden on the already strained health system. 2, 4 Survival rates for cancer are on the rise owing to development of more effective chemotherapeutic regimens. 5, 6 A paradoxical concern emerging from this breakthrough in health care is that affected individuals often must live with permanent side effects resulting from chemotherapy, including hearing loss (ototoxicity) from treatment with drugs such as cisplatin. 7 Cisplatininduced hearing loss is characterised by a bilateral, irreversible and high-frequency sensorineural hearing loss. The hearing loss is irreversible because once destroyed by cisplatin-based chemotherapy, mammalian hair cells cannot regenerate. 4 The pathophysiology of ototoxicity has been extensively discussed in previous research, 7, 8 with recent evidence suggesting a hyperaccumulation of cisplatin within the cochlea as the reason behind ototoxicity. 9 Incidence of cisplatin-induced ototoxicity has been reported to vary from as low as 0% to as high as 100% amongst patients in different studies. 4 In one of the few South African studies on the topic, incidence of ototoxicity was reported to be 55.1%.
There are several factors that have been reported to increase a patient's susceptibility to hearing loss owing to cisplatinbased chemotherapy. 4, 8 Amongst them are cumulative dosage, 4 renal insufficiency, 7 age, 11, 12 pre-existing hearing loss, 10 infusion rate 12, 13, 14 and genetic predisposition. 15 At present, it is not possible to determine, beforehand, an individual's susceptibility or risk of developing ototoxicity following treatment with cisplatin-based chemotherapy. 13 Therefore, the most common strategy currently used to prevent ototoxicity owing to cisplatin-based chemotherapy is to prospectively monitor patient's hearing thresholds throughout their chemotherapy treatment, also known as ototoxicity monitoring. 12, 14, 15, 16, 17, 18 This allows a physician to choose from several medical interventions, once a decline in a patient's hearing sensitivity is noted, to prevent further progression in hearing loss. 14, 15, 16 The medical interventions that are reportedly used to prevent further deterioration in patient's hearing thresholds during cisplatin chemotherapy are: discontinuing the administered medication, adjusting the dosage of medication, changing the frequency of drug administration, switching to a less ototoxic drug or continuing with the medication for which they would have to prepare the patient and family on coping strategies to adjust to the hearing loss. 10, 12 Currently, there is limited evidence on the effectiveness of these treatment modification strategies implemented post detection of deterioration in hearing, especially in the adult population. 10 Use of lower cumulative cisplatin doses or less ototoxic medications such as Carboplatin has not been implemented as a standard preventative strategy for cisplatin-induced ototoxicity in clinical practice, because it is unclear whether these modifications would fully keep the antitumour efficacy. 16 Nevertheless, modification strategies are often implemented as part of treatment protocols for specific cancerous tumours. 17, 18, 19, 20 For example, interventions to change the dosage and type of drug, respectively, to prevent further deterioration in hearing once it is detected have been recommended for tumours such as medulloblastoma. 19 Use of cisplatin as a therapeutic agent has been found to successfully lead to remission in various cancerous tumours despite side effects such as ototoxicity. Thus, therapeutic agency often takes precedence over subsequent risk of developing ototoxicity when using this drug during chemotherapy. 9 Given the high success rates of current chemotherapy treatments, many cancer survivors must live with the ototoxic side effect from mainline drugs like cisplatin. It is therefore imperative, now more than ever, to focus on measures that can be taken to ensure excellent quality of life post treatment. The current study will help to bridge the gap in literature by providing data that evaluate, in a descriptive and comparative manner, the different preventative audiological measures used when cisplatinbased ototoxicity has been detected, to determine to what extent each of them is effective in preserving patients' hearing thresholds during chemotherapeutic treatment.
Methods
A retrospective medical folder review design 21 and purposive sampling were used to select medical records of all patients who underwent cisplatin-based chemotherapy in the Department of Radiation Oncology at Groote Schuur Hospital (GSH) while receiving regular ototoxicity monitoring services in the Audiology department between 2011 and 2016. Only medical folders that had at least three audiograms obtained at the start (baseline), during (checkup) and end (exit) of chemotherapy were included for review. Medical folders of patients who had a pre-existing hearing loss prior to baseline audiogram, an indication of middle ear pathology, simultaneous treatment with ototoxic medications (e.g. aminoglycosides and loop diuretics) and radiation therapy treatment for head and neck cancers were excluded from the review.
The following data were extracted from the medical records using a self-developed data abstraction sheet -demographic, medical (chemotherapy) and audiometric data. The extracted data were kept in a password-secured electronic Google spreadsheet. A new study number, consisting of a combination of three letters and three numbers, was allocated to each folder to ensure that no patient names were recorded. Patients at this facility had their hearing status assessed prior to the start of cisplatin chemotherapy (baseline audiometry) and before each cycle of chemotherapy treatment until they completed their treatment. The following audiometric tests were used to monitor patients' hearing thresholds -otoscopy, tympanometry and pure tone audiometry (250 Hz -8000 Hz). The Common Terminology Criteria of Adverse Events version 4 (CTCAE v4) grading scale was used to determine whether the patient's hearing thresholds were changing during chemotherapy treatment and to grade the severity of hearing loss in the current study population. 21 The CTCAEv4 is the most commonly used, valid and widely accepted hearing loss grading scale in oncology literature and clinical trials. 21 It describes incidence and specifies the severity of hearing loss. It uses four grades of hearing loss which combines objective and subjective hearing assessments in rating hearing. Category zero represents no hearing loss and subsequent grades represent increasing severity of hearing loss, respectively. 22, 23, 24 R, a statistical environment used for statistical analysis and graphics was used 25 to analyse the data. Figures, graphs and tables were used to summarise, describe and arrange the data into organised visual presentations. The Chi-square test was used to assess for significant associations between categorical variables. 
Results
A total of 680 medical folders of patients who received cisplatin-based chemotherapy at GSH oncology department between 2011 and 2016 were accessed for review. Out of these, 128 folders met the inclusion criteria for this study. However, only 58 of the folders that met the inclusion criteria had information on the type and dose of chemotherapy drug used. Table 1 presents a description of patients whose folders were included in this study.
Fifty-eight patients started with cisplatin at baseline audiogram visit. At the time of the exit audiogram, this number was reduced to 44 patients. Median cisplatin cumulative dose during treatment was 465 mg/m². In terms of drug dose, median single dose for cisplatin remained relatively unchanged throughout treatment (see Figure 1 ).
With regard to treatment modification to minimise further deterioration of hearing loss during cisplatin chemotherapy treatment, three dominant strategies were found to be used at GSH: Switching the patient to a different drug, adjusting or reducing the patient's dosage or continuing the same treatment regimen (without dosage adjustment). Figure 2 provides a summary of the types of strategies implemented and the proportions of patients under each one.
The CTCAEv4 criteria were used to grade presence and severity of hearing loss. Incidence of ototoxicity and severity of hearing loss according to the different treatment modifications at the end of treatment are presented in Table 2 .
The Chi-square test showed no significant association between treatment modifications and incidence of hearing loss as classified by the CTCAEv4 grading criteria (χ 2 = 2.33, df = 2, p = 0.31, p < 0.05).
Discussion
This study set out to determine the efficacy of strategies used to prevent or minimise cisplatin-induced hearing loss in chemotherapy patients seen jointly by the departments of Oncology and Audiology as outpatients at GSH between the years 2011 and 2016. There were three common strategies that were implemented by the Department of Radiation Oncology at GSH when a patient's hearing thresholds showed signs of deterioration -adjust (reduce) the drug dosage, switch the patient to a less ototoxic drug and no modification (i.e. continue with the original treatment plan). Overall, the findings of the study indicated that despite a variety of treatment modifications being implemented when a change in patient's hearing threshold is detected, the majority of the patients continue to experience a significant deterioration in their hearing thresholds following treatment in all the noted sub-groups. The result showing no statistically significant association between treatment modifications and incidence of hearing loss was an unexpected finding in this study. This is because one of the premises upon which About half (50%) of the patients whose cisplatin dose was adjusted (reduced) continued to experience a deterioration in their hearing thresholds post treatment modification. This was consistent with the findings of previous studies which reported a continuation of the deterioration of hearing thresholds post cisplatin dose adjustment or reduction. 18, 19, 20 Therefore, while it may seem intuitive that a reduction in drug dose should lead to less deterioration of hearing thresholds owing to cisplatin-induced chemotherapy, none of the studies reviewed thus far 18, 19, 20 and also the findings of this study seem to support that.
A possible explanation for the observed lack of effectiveness of the dose reduction strategy could be inadequacy of the audiometric test used to monitor patients' hearing thresholds to provide early warning signs when patients' hearing thresholds start to deteriorate. For instance, in this study, and all other studies reviewed which reported implementing of dose reduction to prevent further deterioration of hearing loss, 18, 19, 20 patients' hearing thresholds were monitored using conventional pure tone audiometry (250 Hz -8000 Hz). This test protocol is only sensitive to ototoxic changes below or equal to 8 kHz. 4 It is therefore highly likely that the ineffectiveness of this strategy as shown in this study, and as reported in other studies that have been reviewed thus far, was mainly owing to the fact that changes in patients' hearing thresholds were detected too late and therefore any intervention that was implemented following that was less likely to be effective. Also, all the studies reviewed that reported the ineffectiveness of the dose reduction intervention involved paediatric populations and could therefore be reflecting a ceiling effect 26 owing to the reflected homogeneity in age group. Studies showing dose reductions in adult populations could not be found and therefore further research is needed which looks at this type of treatment modification in the adult population.
Another strategy that was implemented at the GSH oncology department to minimise further deterioration of patient hearing thresholds during cisplatin-based chemotherapy was to switch the patient from cisplatin to Carboplatin. Carboplatin is known to be less ototoxic than cisplatin. 6 However, this strategy was also found not to be effective in preventing further deterioration of patients' hearing threshold. Patients who were managed using this strategy showed the highest incidence of ototoxicity when compared to those who were managed using other strategies. This was consistent with the findings of previous studies 18, 20 who also reported that this strategy was ineffective. This could potentially be because of the fact that patients who are switched from cisplatin to Carboplatin are likely to be those who are already showing susceptibility to ototoxicity. Therefore, these are patients who are likely to lose their hearing regardless of the ototoxic drug used. Therefore, switching them from cisplatin to Carboplatin which is also ototoxic is less likely to be effective. Reports from previous studies also seem to suggest that simultaneous use of ototoxic medication is a risk factor on its own. 4, 6 Based on the studies reviewed thus far and the findings of this study, there appears to be a synergistic effect between cisplatin and Carboplatin therapy which increases a patient's risk of developing hearing loss during chemotherapy as evidenced by the high incidence of hearing loss in that group, and it causes more severe hearing loss when compared to other treatment modification groups.
The last strategy implemented was to continue with the original treatment plan (i.e. no treatment modification). For patients for whom this strategy was implemented, the study revealed a large proportion of patients with ototoxicity at the exit stage, which was also consistent with the findings of previous studies. 10, 27, 28, 29 However, an unexpected finding from this study was that incidence of ototoxicity in patients who were managed using this strategy was comparable to that of patients who were managed using the other two strategies. It was expected that more patients who were managed using this strategy will experience a significant deterioration in hearing thresholds when compared to patients in the other two strategies; however, that was not the case. A possible explanation for this finding could be that patients who were managed using this strategy were those who showed better tolerance to cisplatin-based chemotherapy (i.e. initially showed less deterioration in hearing thresholds) and therefore were not prioritised for any treatment modification.
The findings of the current study should be interpreted while considering its methodological limitations and study design. That is, the current study was a retrospective record review, no extended high-frequency audiometry data was obtained and no audiological follow-up of patients post chemotherapy occured. Retrospective studies rely on how accurate the written records are and face difficulty when controlling for bias because there is no implementation of blinding and randomisation. 21 Also, only 58 of 680 files reviewed in this study fulfilled the inclusion criteria. This impacted on the sample size and resultantly the power of the study which enabled significant associations to be made. Lack of longterm and follow-up audiologic data meant that the current study could not assess for changes in incidence and progression of ototoxicity post treatment. Several studies have reported development of ototoxicity post treatment. 9 This highlights the importance of long-term follow-up with suggestions for long-term follow periods of up to 10 years.
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The author also acknowledges that modifications to cisplatin chemotherapy treatment are not made only for the purpose of preventing ototoxicity.
However, despite its limitations, this is one of a handful of studies in South Africa that sought to overtly document and assess the effectiveness of current measures used to prevent further deterioration of patients' hearing thresholds during cisplatin chemotherapy. The study also revealed that conventional audiometric monitoring for ototoxicity, although widely and commonly implemented, potentially causes delays in identification of patients who are at risk of developing significant hearing loss and this could potentially render resultant treatment modifications ineffective. The outcomes from this study highlight the need for evidencebased ototoxicity prevention protocols that will ensure timeous intervention should a patient develop hearing loss while being treated using cisplatin.
Conclusion
This study revealed that current strategies implemented at Department of Radiation Oncology at GSH, namely change in dosage, change in type of drug and continuation with the same treatment regimen, were ineffective in preventing or minimising further deterioration of patients' hearing thresholds during cisplatin chemotherapy. Further research is therefore recommended to investigate the rationale behind the treatment modifications chosen in the clinical settings when ototoxicity develops as well as to try to document the effectiveness of different treatment modifications and/or intervention strategies. Findings of this study also seem to suggest that more effective and sensitive ototoxicity monitoring protocols for early detection of hearing loss in patients during cisplatin chemotherapy treatment may be more useful than conventional audiometry. More sensitive ototoxicity monitoring protocols such as the ones that include extended high-frequency audiometry (9 kHz -16 kHz) and Distortion Product Otoacoustic Emission measures should therefore be advocated for and implemented as best practice when monitoring chemotherapy patient's hearing thresholds. 30, 31 
